Injection-based drug delivery may replace cancer infusion drips

Source: interestingengineering
Author: @IntEngineering
Published: 8/20/2025
To read the full content, please visit the original article.
Read original articleA Stanford research team has developed a novel drug delivery platform that could transform cancer and autoimmune disease treatments by replacing lengthy intravenous (IV) infusions with quick, high-concentration injections that patients can self-administer at home. The innovation centers on a specially designed polyacrylamide copolymer called MoNi, which stabilizes protein-based drugs at concentrations exceeding 500 mg/mL—more than double typical levels—without causing clumping or loss of efficacy. This is achieved by spray-drying protein molecules coated with MoNi into fine, glassy microparticles that remain stable under stress, including freeze-thaw cycles and high temperatures, and can be smoothly injected through tiny needles.
The technology has been successfully tested on proteins such as albumin, human immunoglobulin, and a COVID antibody treatment, demonstrating broad applicability across biologic drugs. MoNi’s mechanical properties, rather than the chemical nature of the proteins, enable this versatility. Preclinical studies have shown no adverse effects, and the platform
Tags
materialsdrug-deliveryprotein-stabilitypolymer-sciencebiomedical-engineeringcancer-treatmentpharmaceutical-technology